Affinity Biosensors

About Affinity Biosensors

Affinity Biosensors, founded in 2006 by Dr. Kenneth Babcock and Dr. Curtis D. Minihane, operates at the intersection of diagnostics and critical care with a focus on combating antimicrobial resistance (AMR). The company is headquartered in Santa Barbara, California. The founders' journey began at the University of California, Santa Barbara (UCSB), where their research into advanced sensor technology laid the groundwork for the company's core intellectual property. This deep expertise in mass measurement at the femtogram level is central to the firm's value proposition.

The company's primary business involves the development and commercialization of rapid diagnostic systems for infectious diseases. Its flagship product, the LifeScale® AST system, addresses a critical bottleneck in patient care: the slow pace of traditional antibiotic susceptibility testing (AST). The system has received FDA clearance, a significant milestone that validates its clinical utility. Affinity Biosensors' business model is centered on selling these diagnostic instruments and associated consumables to healthcare institutions, such as hospitals and clinical laboratories. The target clients are clinicians and lab technicians in critical care settings who require timely data to make informed treatment decisions for patients with life-threatening infections.

The LifeScale system differentiates itself by providing phenotypic AST results directly from positive blood cultures in approximately 4.5 hours, a substantial improvement over conventional methods that can take days. This is achieved through a microfluidic sensor that measures the mass of individual bacteria with extreme precision. By monitoring changes in bacterial mass in the presence of various antibiotics, the system can quickly determine which drugs will be effective. This capability not only enables more targeted and timely antibiotic therapy but also supports antimicrobial stewardship programs within hospitals by reducing the use of broad-spectrum antibiotics. The company is actively expanding its diagnostic platform to include rapid antifungal susceptibility testing, targeting urgent threats like Candida auris.